EVRZF yields 77.87% · JNJ yields 2.13%● Live data
📍 EVRZF pulled ahead of the other in Year 1
Combined, EVRZF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EVRZF + JNJ for your $10,000?
EVRAZ plc, together with its subsidiaries, engages in the production and distribution of steel and related products in Russia, the Americas, Asia, Europe, CIS, Africa, and internationally. It operates through four segments: Steel; Steel, North America; Coal; and Other Operations. The company offers steel and value-added products, including infrastructure steel, rails, large-diameter pipes, and oil country tubular goods. It also extracts vanadium ores; processes and produces vanadium products; and mines and enriches iron ore and coal. In addition, the company engages in the energy-generating, shipping, and railway transportation businesses. It offers its products for use in infrastructure and construction projects; and rail, energy, and industrial end-user markets, as well as coke and steel producers. The company was formerly known as Project Savannah PLC and changed its name to EVRAZ plc in October 2011. EVRAZ plc was founded in 1992 and is based in London, the United Kingdom.
Full EVRZF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.